Seliciclib (roscovitine or CYC202) is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that ...
(R)-Roscovitine (Seliciclib) is an orally bioavailable and selective CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, ...
Seliciclib has been shown to inhibit RNA polymerase II-dependent transcription and down-regulation of the protein MCL1. Roscovitine inhibits in vitro M-phase- ...
Roscovitine, also known as seliciclib or CYC202, is a selective cyclin-dependent kinases (cdk), which are essential cell cycle regulators frequently ...
Roscovitine (Seliciclib, CYC202) is a potent and selective inhibitor of cyclin-dependent kinases (cdks). Find all the information about Roscovitine ...
#12.
Selleck Chemical LLC Roscovitine (Seliciclib) 10mg 186692 ...
Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free ...
cyclin H, and CDK9/cyclin T. Seliciclib induces apoptosis from all phases of the cell cycle in tumor cell lines, reduces tumor growth in xenografts in nude ...
#14.
Seliciclib | Cyclacel Pharmaceuticals, Inc.
Seliciclib. Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial. Medicine 2020 ...
#15.
SELICICLIB - Inxight Drugs
Seliciclib (CYC202, R-roscovitine) is a second-generation orally available cyclin-dependent kinases (CDKs) inhibitor that competes for ATP binding sites on ...
#24.
Phase I evaluation of seliciclib (R-roscovitine ... - ResearchGate
Request PDF | Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies ...
Seliciclib, also known as roscovitine and CYC202, is a n orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential ...
#26.
From Roscovitine to CYC 202 to Seliciclib
From Roscovitine to CYC202 to Seliciclib – from bench to bedside: discovery and development Nikolai Zhelev, Dimitar Trifonov, Shudong Wang, Moustapha Hassan ...
#27.
(R)-Roscovitine - Cayman Chemical
CAS Number. 186692-46-6 ; Synonyms. Seliciclib ; Molecular Formula. C19H26N6O ; Formula Weight. 354.5 ; Purity. ≥98%.
#28.
R-Roscovitine (Seliciclib) prevents DNA damage-induced ...
R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair · Abstract ...
#29.
Seliciclib (Roscovitine) Supplier | CAS 186692-46-6| AOBIOUS
View and buy high purity Seliciclib (Roscovitine) from AOBIOUS, the leading supplier of life science reagents.
Seliciclib is an orally active cyclin-dependent kinase (CDK) inhibitor being developed by Cyclacel Pharmaceuticals for the treatment of cancer and certain.
#31.
Seliciclib (CYC202; r-Roscovitine) in Combination with ...
inhibitor seliciclib (CYC202, R-roscovitine) when used alone or in combination with paclitaxel was studied in uterine cancer cell.
Find and order inhibitors and products like this Roscovitine (CYC202,Seliciclib) on www.anticorps-enligne.fr. Commandez ABIN3221755.
#33.
RRC Ligand Summary Page - RCSB PDB
R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and ...
#34.
Roscovitine - 亞旭生物科技
Roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, ...
#35.
Drug: Seliciclib - Cancerrxgene
cnaPANCAN194 Wild type
Number of cell lines 22 370
Median 41.523 48.483
Geometric mean (red line) 44.407 53.490
Moreover, Seliciclib also suppressed the migration of MG-63, suggesting a potential application for Seliciclib in bone defect repair and ...
#39.
In vitro activity of cyclin-dependent kinase inhibitor CYC202 ...
CYC202 (Seliciclib, R-roscovitine; Cyclacel Ltd., Dundee, UK) is a purine analogue and a selective inhibitor of the cdk2–cyclin E as well as cdk7–cyclin H ...
#40.
Seliciclib | CDK - 陶术生物
Roscovitine 是Cdk2/cyclin E 的有效抑制剂，IC50为0.1 µM。它还抑制Cdk7/cyclin H、Cdk5/p35 和Cdc2/cyclin B，IC50为0.49、0.16和0.65 µM。
#41.
Full article: Seliciclib in malignancies - Taylor & Francis Online
Seliciclib (CYC202, R-roscovitine) is a second-generation CDK inhibitor that competes for ATP binding sites on these kinases, reducing tumor ...
#42.
CHEMBL14762 Name - Compound Report Card
Name: SELICICLIB. Max Phase: Phase 2 Learn more. Molecular Formula: C19H26N6O. Molecular Weight: 354.46. ChEMBL Synonyms:.
#43.
A phase I trial of the selective oral cyclin-dependent kinase ...
Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and 9 to enter ...
BioCrick is a famous high-purity reference standards manufacturer. Our Roscovitine (Seliciclib,CYC202) is confirmed by NMR. Order now can get a discount!
#45.
Seliciclib - Small Molecule (ID:10001-101) - HMS LINCS Project
(R)-Roscovitine (Seliciclib) is an orally bioavailable and selective CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, ...
#48.
Roscovitine (Seliciclib) - AllgenBio
Seliciclib, also known as roscovitine and CYC202, is a n orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential ...
Roscovitine (CYC202, Seliciclib, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in ...
#52.
ImmunoWay Biotechnology Company |抗体|病理抗体|诊断抗体
Roscovitine (Seliciclib, CYC202, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p53 with IC50 ...
Seliciclib, a cyclin-dependent kinase inhibitor, is a promising candidate to treat a variety of cancers. Pharmacokinetic studies have shown ...
#54.
seliciclib | Ligand page - Guide to MALARIA PHARMACOLOGY
Comment: Seliciclib inhibits cyclin-dependent kinases (CDKs) 2, 7 and 9. Click here for help ...
#55.
Seliciclib - chemeurope.com
R-roscovitine (Seliciclib or CYC202) is a trial drug in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit ...
#56.
Phase I evaluation of seliciclib (R-roscovitine), a novel oral ...
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.
#57.
US9872874B2 - Dosage regimen for sapacitabine and seliciclib
Seliciclib has been demonstrated to be a potent inhibitor of cyclin dependent kinase enzymes, particularly CDK2. This compound is currently in development as an ...
Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free ...
#59.
seliciclib - Wiktionary
PronunciationEdit · IPA: /ˌsɛlɪˈsɪklɪb/. NounEdit. seliciclib (uncountable). A drug being researched for the treatment of certain lung cancers and other ...
#60.
Treatment of Cushing Disease With Pituitary-Targeting Seliciclib
AbstractContext. Preclinical studies show seliciclib (R-roscovitine) suppresses neoplastic corticotroph proliferation and pituitary adrenocorticotrophic ...
#61.
an open-label, dose-finding, phase 1b trial - The Lancet
Seliciclib is an orally available cyclin-dependent kinase inhibitor that suppresses proliferation of synovial fibroblasts—cells not yet ...
#62.
Roscovitine (Seliciclib, CYC202) (S1153-10000) bei Hölzel ...
Roscovitine (Seliciclib, CYC202, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p53 with ...
#63.
Phase I study of seliciclib (CYC202 or R ... - DIAL@UCLouvain
Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer ...
#64.
R-Roscovitine (Seliciclib) prevents DNA ... - TUScholarShare
R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair · DOI. 10.1186/1476-4598-9 ...
#65.
Cyclacel Announces Topline Results From The Appraise ...
Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and ...
#66.
Seliciclib Inhibits Renal Hypertrophy but Not Fibrosis in the ...
Seliciclib 28 mg/kg inhibited both CRG by 45% and increased kidney protein by 48% without affecting increased kidney DNA. Chronically, SNx rats ...
#67.
Cyclacel Pharmaceuticals, Inc. Ends Phase 2b Study of ...
Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and ...
Seliciclib (CYC202, R-roscovitine) is a cyclin-dependent kinase (CDK) inhibitor that competes for the ATP binding site on the kinase.
#69.
Seliciclib (CYC202, R-roscovitine) enhances the antitumor ...
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Maria Virginia C. L. ...
#70.
Seliciclib | C19H26N6O - ChemSpider
Structure, properties, spectra, suppliers and links for: Seliciclib, 186692-46-6.
#71.
The effects of the CDK inhibitor seliciclib alone or in ...
Cell lines used: SK-UT-1, SK-UT-1b and SK-LMS-1, the cytotoxicity of seliciclib and cisplatin was measured by the MTT assay. In.
#72.
Characterization of Cyclin E Expression in Multiple Myeloma ...
Combination of seliciclib with flavopiridol effectively reduced CCNE1 and CCND1 protein levels, increased subG1 apoptotic fraction and promoted MM cell death in ...
#73.
Phase I study of sapacitabine and seliciclib in ... - X-MOL
Seliciclib is an oral CDK2, 7 and 9 inhibitor, and sensitizes cells to CNDAC by decreasing DSB repair via compromise of HR protein ...
#75.
Safety and pharmacokinetics of Roscovitine (Seliciclib) in ...
Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, ...
#76.
Pituitary-targeting seliciclib may warrant further investigation ...
Pituitary-targeting seliciclib may improve hypercortisolemia in patients with Cushing's disease, suggest preliminary study results.
#77.
Seliciclib CAS No. : 186692-46-6 - Chemscene
ChemScene Provide Seliciclib(CAS 186692-46-6)In-stock or Backordered impurities,Bulk custom synthesis,Formular C19H26N6O,MW 354.45 bulk manufacturing, ...
#78.
Cyclacel's cancer drug seliciclib fails to meet endpoints in ...
Cyclacel's cancer drug seliciclib fails to meet endpoints in phase IIb study. Berkeley Heights, New Jersey | Thursday, December 23, 2010, 14:00 Hrs [IST].
#79.
Roscovitine | CAS 186692-46-6 - Santa Cruz Biotechnology
Roscovitine is an inhibitor of Cdk7, cyclin B, cyclin E, cyclin A, cyclin H, cdc2 and p53. Références. The cyclin-dependent kinase inhibitor seliciclib (R- ...
#80.
Cyclacel enrols first patient in seliciclib's trial for Cushing's ...
Seliciclib is an orally-available CDK2/9 inhibitor that was already assessed in around 450 patients and is currently being evaluated in ...
#81.
Cyclin-dependent kinase 2 inhibitor - LINCS Data Portal
(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastorna cells to nutlin-3-induced apoptosis. In this study, we have analyzed the consequences ...
#85.
Phase I study of sapacitabine and seliciclib in ... - ecancer
Dr Tolaney speaks with ecancertv at ASCO 2016, presenting her research on combined sapacitibine/seciciclib therapy in BRCA tumours.
#86.
Multicenter Study of Seliciclib (R-roscovitine) for Cushing ...
This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients with newly diagnosed, ...
#87.
Multicenter Study of Seliciclib | Clinical Trials | medthority.com
Brief Summary: This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients ...
#88.
Likelihood of Approval and Phase Transition Success Rate ...
Seliciclib (CYC-202) is under development for the treatment of rheumatoid arthritis, Cushing's disease and cystic fibrosis.
#89.
Evaluation of Fadraciclib and Seliciclib to Promote Apoptosis ...
Previously published research from The University of Edinburgh and other investigators have found that CDK inhibitors, including seliciclib, ...
#90.
Seliciclib - Therapy Detail - The Jackson Laboratory
Therapy Name, Seliciclib. Synonyms. Therapy Description. Roscovotine (seliciclib) inhibits Cdc2, Cdk2 and Cdk5, which results in disruption of cell-cycle ...
#91.
Effect of Seliciclib (CYC202, R-Roscovitine) on Lymphocyte ...
We conducted a study to evaluate whether the cyclin-dependent kinase inhibitor seliciclib affected rat lymph node cells (LNc) activation and ...
#92.
The effects of the CDK inhibitor seliciclib alone or in ...
The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines - University of Surrey - Journal ...
#94.
Cyclacel's Seliciclib to be Evaluated in - GlobeNewswire
Cyclacel Pharmaceuticals logo. Cyclacel's Seliciclib to be Evaluated in Investigator-Initiated Clinical Study to Treat Rheumatoid Arthritis.
#95.
Seliciclib - Wikiwand
Seliciclib is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase inhibitors that preferentially inhibit multiple enzyme ...
#96.
Phase I study of sapacitabine and seliciclib in patients ... - Vimeo
Dr Tolaney speaks with ecancertv at ASCO 2016, presenting her research on combined sapacitibine/seciciclib therapy in BRCA tumours.
#97.
Seliciclib (Roscovitine) is an Orally Active and Selective CDKs ...
Seliciclib (Roscovitine or CYC202) is a potent, selective and orally active CDKs inhibitor. Seliciclib preferentially inhibits CDK2, ...
#98.
How to Pronounce Seliciclib - YouTube
This video shows you how to pronounce Seliciclib … Show more. Show more. Show less. 161 views • Jun 1, 2015 ...
#99.
Cell Cycle Proteins—Advances in Research and Application: ...
“Phase I study of seliciclib (CYC202, R-roscovitine), an inhibitor of cyclin-dependent kinases 2, 7 and 9, causing cell cycle changes and apoptosis in ...
#100.
Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
Seliciclib has been shown to inhibit the phosphorylation ... Moreover, seliciclib has also been tested for its ability to inhibit other CDKs.
seliciclib 在 How to Pronounce Seliciclib - YouTube 的推薦與評價
This video shows you how to pronounce Seliciclib … Show more. Show more. Show less. 161 views • Jun 1, 2015 ... ... <看更多>